| Assessment Status | Pre submission consultation scheduled |
| HTA ID | 23071 |
| Drug | Ritlecitinib |
| Brand | Litfulo® |
| Indication | For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. |
| Assessment Process | |
| Rapid review commissioned | 27/11/2023 |
| Rapid review resubmission required | 11/12/2023 |
| Rapid review completed | 22/12/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ritlecitinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/01/2024 |
